Plain-English translation of NCT07286058 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a continuation study for people with psoriatic arthritis who already completed a 1-year trial of a medication called . The study will follow you for up to 2 more years to see how safe this medication is and how well it continues to work for your joint pain and skin symptoms.
While shorter trials can show whether a medication works, doctors need to understand how safe and effective it is over many months or years of regular use, especially for a long-term condition like psoriatic arthritis.
You likely qualify if…
You likely don't qualify if…
You will take a daily tablet of the medication (at the same dose you were taking, or a newly assigned dose if you were on a comparison treatment in the earlier trial) for up to 2 years. You will have regular clinic visits to check your joint symptoms, skin, and overall health, with a final follow-up visit about one month after you stop the medication.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States
Sponsor
Takeda
Enrollment target
~1,182 participants
Started
March 2026
Primary completion
December 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Takeda Contact
Takeda
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.